Prestige BioPharma Limited (KRX:950210)
9,560.00
+450.00 (4.94%)
Apr 16, 2026, 1:40 PM KST
Prestige BioPharma Revenue
Prestige BioPharma had revenue of 7.70B KRW in the quarter ending December 31, 2025, with 147.35% growth. This brings the company's revenue in the last twelve months to 19.02B, up 224.15% year-over-year. In the fiscal year ending June 30, 2025, Prestige BioPharma had annual revenue of 14.33B with 1,978.97% growth.
Revenue (ttm)
19.02B
Revenue Growth
+224.15%
P/S Ratio
5.76
Revenue / Employee
n/a
Employees
54
Market Cap
109.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 14.33B | 13.64B | 1,978.97% |
| Jun 30, 2024 | 689.08M | 527.23M | 325.77% |
| Jun 30, 2023 | 161.84M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Macrogen | 195.27B |
| ORIENT BIO | 59.09B |
| Amicogen | 41.98B |
| CG Invites | 27.39B |
| GeneOne Life Science | 23.04B |
| iNtRON Biotechnology | 5.74B |
| IMB Dx | 5.33B |
| ENCell | 5.26B |